EUVIMEDEUVIMED entdecken
Crossref

Reprogramming Glucose Metabolism of Macrophage for Acute Liver Failure Therapy with Itaconate Lipo‐Nanodrug

Chen Qiu, Wei Zhang, Yanan Zhao, Tian Han, Wende Yang, Yajing Liu, Peile Jin, Jifan Chen, Xintao Shuai, Jie Ren, Pintong Huang iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202500019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Chen Qiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound in Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009…. Hauptthemen laut MEDLINE: Succinates, Macrophages, Liver Failure, Acute, Glucose. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute liver failure (ALF) is a life‐threatening disease featuring comprehensive inflammatory response and metabolic disorders in which macrophages exert central roles. A glucose metabolism mediator of macrophages, itaconate, has demonstrated potent anti‐inflammatory efficacy in various diseases, implying that itaconate could work in treating ALF. However, systemic administration of itaconate may lead to immune disorder, making targeting the delivery of itaconate to the liver lesion area highly important. Herein, a liposomal nanodrug incorporating itaconate is developed, and its potential in treating acute liver failure in an ALF murine model established by LPS/D‐GalN administration is tested. The nanodrug shows preferential liver accumulation to effectively alleviate LPS/D‐GalN‐induced hepatic histopathological injury by decreasing oxidative stress. Moreover, it reprograms the glucose metabolism of macrophages, resulting in macrophage repolarization toward the anti‐inflammatory phenotype. Furthermore, western‐blot and immunohistochemical assays verifies that the nanodrug may inhibit aerobic glycolysis of macrophages in an NRF2 and STING‐dependent manner. These results underline the promise of the nanodrug for ALF treatment by reprogramming glucose metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SuccinatesMacrophagesLiver Failure, AcuteGlucoseNanoparticlesAnimalsMiceMaleLipopolysaccharidesMice, Inbred C57BLLiposomesLiverRAW 264.7 CellsOxidative StressNF-E2-Related Factor 2Disease Models, Animal

Stichwörter der Autor:innen

acute liver failureliposomemacrophage repolarization

Substanzen

Succinatesitaconic acidGlucoseLipopolysaccharidesLiposomesNF-E2-Related Factor 2

Autor:innen und Institutionen

  • Department of Ultrasound in Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Research Center of Ultrasound in Medicine and Biomedical Engineering, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Department of Medical Ultrasound, Laboratory of Novel Optoacoustic (Ultrasonic) Imaging, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.
  • Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
  • Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
  • Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou, 310009, China.

ORCID-Profile: Pintong Huang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • China Postdoctoral Science Foundation

Zitieren

APA

Qiu, C., Zhang, W., Zhao, Y., Han, T., Yang, W., Liu, Y., Jin, P., Chen, J., Shuai, X., Ren, J., & Huang, P. (2025). Reprogramming Glucose Metabolism of Macrophage for Acute Liver Failure Therapy with Itaconate Lipo‐Nanodrug. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500019

Vancouver

Qiu C, Zhang W, Zhao Y, Han T, Yang W, Liu Y, et al. Reprogramming Glucose Metabolism of Macrophage for Acute Liver Failure Therapy with Itaconate Lipo‐Nanodrug. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500019

BibTeX
@article{Qiu2025,
  author = {Qiu, Chen and Zhang, Wei and Zhao, Yanan and Han, Tian and Yang, Wende and Liu, Yajing and Jin, Peile and Chen, Jifan and Shuai, Xintao and Ren, Jie and Huang, Pintong},
  title = {Reprogramming Glucose Metabolism of Macrophage for Acute Liver Failure Therapy with Itaconate Lipo‐Nanodrug},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202500019}
}
Kostenlos starten →